Sensitive Cyp3a Substrates Interactions

Ivosidenib induces CYP3A4, decreasing concentrations of sensitive substrates and risking loss of therapeutic effect. Avoid concomitant use.

Source: NLP:ivosidenib

Acoramidis inhibits CYP2C9 and may increase substrate concentrations. Monitor patients for signs of increased exposure and toxicity.

Source: NLP:acoramidis hydrochloride

COPIKTRA increases AUC of sensitive CYP3A4 substrates, which may increase the risk of toxicities. Monitor for signs of toxicities and consider reducing substrate dose.

Source: NLP:duvelisib

Dosage modification of sensitive CYP3A substrates may be required when initiating or discontinuing JOURNAVX. JOURNAVX is a CYP3A inducer that may reduce exposure of CYP3A substrates.

Source: NLP:suzetrigine